<![CDATA[Byondis B.V. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=48158>Sat, 11 Apr 2026 10:34:40 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Byondis Appoints Christoph Korpus, PhD, MBA as Chief Executive Officer]]>https://www.newswire.co.kr/newsRead.php?no=1032147Fri, 10 Apr 2026 15:35:00 +0900<![CDATA[비욘디스, 크리스토프 코르푸스 박사를 최고경영자로 임명]]>https://www.newswire.co.kr/newsRead.php?no=1032148Fri, 10 Apr 2026 15:35:00 +0900<![CDATA[Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors]]>https://www.newswire.co.kr/newsRead.php?no=1012472Wed, 04 Jun 2025 15:15:00 +0900<![CDATA[비욘디스, 진행성 또는 전이성 고형 종양 환자를 대상으로 한 새로운 SIRPα 지향 단클론 항체 BYON4228의 임상 1상 시험에서 첫 환자 투여 발표]]>https://www.newswire.co.kr/newsRead.php?no=1012474Wed, 04 Jun 2025 15:10:00 +0900